Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Aging-Well: Remote Monitoring for Adults at Risk for Alzheimer's Disease

Start: September 1, 2018
End: June 2023
Enrollment: 100

What Is This Study About?

This observational study will use sensors in the home environment to capture changes in routine daily activities that may signal cognitive or functional decline in older adults with and without mild cognitive impairment. Participants will have a technology platform installed in their home environment for up to four years. The platform is designed to detect changes in daily activities, such as taking medications, using the computer, and driving, that could signal cognitive changes. It will include an electronic pillbox, software installed on the participants' home computer/laptop/tablet, and wireless sensors placed in their car. Participants will also complete baseline and annual study assessments and tests, as well as weekly and monthly online surveys. Researchers are investigating the approaches used in this study to help identify and monitor increasing risks for worsening cognitive function.

Do I Qualify To Participate in This Study?

Minimum Age: 65 Years

Maximum Age: N/A

Must have:

  • Taking at least one medication daily
  • Living within 15 miles of study site
  • Vision and hearing corrected to normal

Must NOT have:

  • Neurodegenerative diseases or dementias, including Alzheimer's, Parkinson's, Huntington's, vascular dementia, Lewy body dementia, and frontotemporal dementia
  • Major neurological disorders (e.g., seizures/epilepsy, stroke or mini-stroke, multiple sclerosis, brain tumor, normal pressure hydrocephalus, brain infection, amyotrophic lateral sclerosis)
  • History of significant brain injuries (e.g., loss of consciousness greater than 10 minutes, permanent brain lesion, anoxic/hypoxic encephalopathy)
  • Major or uncontrolled/unstable physical condition or illness, inculding chronic kidney disease, uncontrolled diabetes, uncontrolled heart disease, uncontrolled chronic obstructive pulmonary disease, and cancer (unless removed/targeted through radiation)
  • History of major psychiatric disorders, including schizophrenia, schizoaffective disorder, bipolar disorder, obsessive-compulsive disorder, or post-traumatic stress disorder
  • Significant neurodevelopmental disorders, such as autism spectrum disorders, attention-deficit/hyperactivity disorder, or intellectual disability
  • Substance use disorder diagnosis or treatment within last year
  • Impaired cognition
  • Loss of use of hands or very limited mobility
  • Exposure to Agent Orange if showing symptoms
  • Chemotherapy

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Jessica Klinger

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

The University of Minnesota and Minneapolis VA Health Care System
Minneapolis, MN 55417
Adreanne Rivera
Oregon Health & Science University
Portland, OR 97239
Adreanne Rivera

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health